Back to Search Start Over

A Multimodal Cardioprotection Strategy During Cardiac Surgery: The ProCCard Study.

Authors :
Chiari P
Desebbe O
Durand M
Fischer MO
Lena-Quintard D
Palao JC
Samson G
Varillon Y
Vaz B
Joseph P
Ferraris A
Jacquet-Lagreze M
Pozzi M
Maucort-Boulch D
Ovize M
Bidaux G
Mewton N
Fellahi JL
Source :
Journal of cardiothoracic and vascular anesthesia [J Cardiothorac Vasc Anesth] 2023 Aug; Vol. 37 (8), pp. 1368-1376. Date of Electronic Publication: 2023 Apr 14.
Publication Year :
2023

Abstract

Objective: The ProCCard study tested whether combining several cardioprotective interventions would reduce the myocardial and other biological and clinical damage in patients undergoing cardiac surgery.<br />Design: Prospective, randomized, controlled trial.<br />Setting: Multicenter tertiary care hospitals.<br />Participants: 210 patients scheduled to undergo aortic valve surgery.<br />Interventions: A control group (standard of care) was compared to a treated group combining five perioperative cardioprotective techniques: anesthesia with sevoflurane, remote ischemic preconditioning, close intraoperative blood glucose control, moderate respiratory acidosis (pH 7.30) just before aortic unclamping (concept of the "pH paradox"), and gentle reperfusion just after aortic unclamping.<br />Measurements and Main Results: The primary outcome was the postoperative 72-h area under the curve (AUC) for high-sensitivity cardiac troponin I (hsTnI). Secondary endpoints were biological markers and clinical events occurring during the 30 postoperative days and the prespecified subgroup analyses. The linear relationship between the 72-h AUC for hsTnI and aortic clamping time, significant in both groups (p < 0.0001), was not modified by the treatment (p = 0.57). The rate of adverse events at 30 days was identical. A non-significant reduction of the 72-h AUC for hsTnI (-24%, p = 0.15) was observed when sevoflurane was administered during cardiopulmonary bypass (46% of patients in the treated group). The incidence of postoperative renal failure was not reduced (p = 0.104).<br />Conclusion: This multimodal cardioprotection has not demonstrated any biological or clinical benefit during cardiac surgery. The cardio- and reno-protective effects of sevoflurane and remote ischemic preconditioning therefore remain to be demonstrated in this context.<br />Competing Interests: Conflicts of Interest None.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1532-8422
Volume :
37
Issue :
8
Database :
MEDLINE
Journal :
Journal of cardiothoracic and vascular anesthesia
Publication Type :
Academic Journal
Accession number :
37202231
Full Text :
https://doi.org/10.1053/j.jvca.2023.04.011